Rising unemployment, escalating health plan costs and 50 million uninsured Americans can’t be ignored. That’s why the House and Senate have outlined bills to increase the number of insured people, improve care quality and outlaw denial of health care for risk reasons. We caught up with Dr. Neal Meropol, section chief of hematology and oncology at University Hospitals, to learn where to get the latest facts on the health care debate.
Use reputable sources. Meropol suggests looking to Web sites such as the Kaiser Family Foundation, PBS or The New York Times — all offer side-by-side comparisons of the House and Senate bills, from eligibility to prescription drug issues.
But be objective. “You’ve got to be careful because a lot of [articles] are going to be colored by politics,” Meropol says. Read newspapers rather than one-sided outlets such as blogs. Or check out educational resources such as The New England Journal of Medicine.
Stay flexible. Keep an open mind while the debate outcome is being decided, Meropol says. “Neither of these plans calls for anybody to alter their current health plan. Both plans on the table will protect individuals.”
Read more at Cleveland Magazine
A minor-league pitcher in his younger days, Richard Armbruster kept playing baseball recreationally into his 70s, until his right hip started bothering him. Last February he went to a St. Louis hospital for what was to be a routine hip replacement.
By late March, Mr. Armbruster, then 78, was dead. After a series of postsurgical complications, the final blow was a bloodstream infection that sent him into shock and resisted treatment with antibiotics.
“Never in my wildest dreams did I think my dad would walk in for a hip replacement and be dead two months later,” said Amy Fix, one of his daughters.
Not until the day Mr. Armbruster died did a laboratory culture identify the organism that had infected him: Acinetobacter baumannii.
The germ is one of a category of bacteria that by some estimates are already killing tens of thousands of hospital patients each year. While the organisms do not receive as much attention as the one known as MRSA — for methicillin-resistant Staphylococcus aureus — some infectious-disease specialists say they could emerge as a bigger threat.
That is because there are several drugs, including some approved in the last few years, that can treat MRSA. But for a combination of business reasons and scientific challenges, the pharmaceuticals industry is pursuing very few drugs for Acinetobacter and other organisms of its type, known as Gram-negative bacteria. Meanwhile, the germs are evolving and becoming ever more immune to existing antibiotics.
“In many respects it’s far worse than MRSA,” said Dr. Louis B. Rice, an infectious-disease specialist at the Louis Stokes Cleveland V.A. Medical Center and at Case Western Reserve University. “There are strains out there, and they are becoming more and more common, that are resistant to virtually every antibiotic we have.”
Read more at CWRUmedicine.org